Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains

Yun Bin Lee, Jeong Hoon Lee, Dong Hyeon Lee, Hyeki Cho, Hongkeun Ahn, Won Mook Choi, Young Youn Cho, Minjong Lee, Jeong Ju Yoo, Yuri Cho, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jung Hwan Yoon, Chung Yong Kim, Hyo Suk Lee

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


The emergence of multidrug-resistant (MDR) strains of hepatitis B virus (HBV) is a major concern. This study aimed to investigate the efficacy and safety of combination therapy with entecavir (ETV) plus tenofovir disoproxil fumarate (TDF) against MDR HBV. To adjust for differences in baseline characteristics, inverse probability weighting (IPW) using propensity scores for the entire cohort and weighted Cox proportional hazards models were applied. Ninety-three consecutive patients who were treated with ETV-TDF combination therapy for > 6 months were included; at baseline, 45 were infected with HBV strains with genotypic resistance to lamivudine (LAM) and ETV (the LAM/ETV-R group), 28 with strains resistant to LAM and adefovir (ADV) (the LAM/ADV-R group), and 20 with strains resistant to LAM, ETV, and ADV (the LAM/ETV/ADV-R group). The median duration of rescue therapy was 13.0 (range, 6.7 to 31.7) months. Seventy-four of 93 patients (79.6%) achieved complete virologic suppression, after a median of 4.5 (95% confidence interval, 3.0 to 6.0) months. The cumulative probability of complete virologic suppression at month 6 was 63.6% (55.7%, 75.0%, and 65.0% in the LAM/ETV-R, LAM/ADV-R, and LAM/ETV/ADV-R groups, respectively). During the treatment period, these probabilities were not significantly different across the resistance profiles before and after IPW (P0.072 and P0.510, respectively). In multivariate analysis, a lower baseline HBV DNA level, but not resistance profiles, was an independent predictor of complete virologic suppression. Renal dysfunction was not observed during the treatment period. In conclusion, rescue therapy with ETV-TDF combination is efficient and safe in patients infected with MDR HBV strains regardless of the antiviral drug resistance profiles.

Original languageEnglish
Pages (from-to)6710-6716
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Issue number11
StatePublished - 1 Nov 2014

Bibliographical note

Publisher Copyright:
© 2014, American Society for Microbiology. All Rights Reserved.


Dive into the research topics of 'Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains'. Together they form a unique fingerprint.

Cite this